117661-72-0

Usage

Uses

Used in Chemical Synthesis:
3,4-Methylenedioxy-6-methylbenzyl chloride is used as a chemical intermediate for the synthesis of various organic compounds. Its unique structure and reactivity allow it to participate in a wide range of chemical reactions, making it a valuable component in the production of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
3,4-Methylenedioxy-6-methylbenzyl chloride is used as a key building block in the development of new drugs. Its versatile chemical properties enable it to be incorporated into the molecular structures of potential therapeutic agents, contributing to the discovery and design of novel pharmaceuticals with improved efficacy and safety profiles.
Used in Agrochemical Industry:
3,4-Methylenedioxy-6-methylbenzyl chloride is used as a starting material in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and stability make it suitable for the creation of effective crop protection products that can help increase agricultural productivity and reduce crop losses due to pests and diseases.
Used in Specialty Chemicals:
3,4-Methylenedioxy-6-methylbenzyl chloride is used as a raw material in the production of specialty chemicals, such as dyes, fragrances, and flavorings. Its unique chemical structure allows it to be transformed into a variety of compounds with specific properties, making it an essential component in the formulation of high-quality specialty products.

Upstream product

• 7145-99-5 5-methyl-1,3-benzodioxole 
• 107-30-2 chloromethyl methyl ether 
• 75-09-2 dichloromethane 
• 60-29-7 diethyl ether 
• 50-00-0 formaldehyd 

Downstream Products

• 184036-34-8 sitaxentan 

Relevant academic research and scientific papers

Methods and compositions for treatment of sleep apnea

Provided herein are methods of treatment of sleep apnea by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.

SUBSTITUTED THIOPHENES

Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Formulations of sitaxsentan sodium

Provided herein are stable lyophilized and oral formulations of sitaxsentan sodium. In certain embodiments the lyophilized formulations provided herein have improved stability upon reconstitution. Also provided are methods of making and using the formulations.

METHODS AN COMPOSITIONS FOR TREATMENT OF AN INTERSTITIAL LUNG DISEASE

Provided herein are methods of treatment of an interstitial lung disease (ILD) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.

CRYSTALLINE N-(4-CHLORO-3-METHYL-5-ISOXAZOLYL)-2-[2-METHYL-4,5-(METHYLENEDIOXY)PHENYLACETYL]-THIOPHENE-3-SULFONAMIDE

Provided herein are polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide and pharmaceutical compositions thereof. Also provided are methods of treatment of endothelin-mediated disorders by administering a polymorph N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide or pharmaceutical compositions thereof.

METHODS AND COMPOSITIONS FOR TREATMENT OF DIASTOLIC HEART FAILURE

Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.

Sulfonamides for treatment of endothelin-mediated disorders

Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides a

Sulfonamides for treatment of endothelin-mediated disorders

Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.